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six hours but not in normal glomeruli. In the group sacrificedL-Arginine supplementation increases mesangial cell injury and
at day 6, day 2 proteinuria was higher in the ATS 1 L-Argsubsequent tissue fibrosis in experimental glomerulonephritis.
group compared with the ATS alone group (P , 0.05). Mea-Background. Mesangial cell lysis in the antithymocyte serum
sures of fibrotic disease at day 6 all showed large increases(ATS)-induced model of glomerulonephritis is dependent on
over control with ATS alone (P , 0.01), and further small,the generation of cytotoxic nitric oxide (NO) through transient
induction of NO synthase (iNOS). We hypothesized that in- but significant increases when L-Arg was combined with ATS
creased availability of l-arginine (L-Arg) during mesangial cell (P , 0.05).
lysis might provide iNOS with increased substrate leading to Conclusions. The results indicate that if given during disease
increased lysis, and that this increased lysis would be reflected induction, L-Arg supplementation can enhance iNOS-depen-
in more severe fibrotic disease at day 6. dent tissue injury by providing increased substrate. Although
Methods. To ensure whole body equilibration with high the increase in injury with L-Arg supplementation was small,
L-Arg at the time of injury, rats were pretreated with 1% L-Arg it led to increased fibrosis at day 6. These data predict that in
in drinking water for one week prior to the administration of diseases with repeated iNOS-dependent tissue injury, L-Arg
ATS. Animals were sacrificed six hours after ATS injection supplementation may produce cumulative increases in tissue
when previous experiments had indicated iNOS induction had fibrosis.
occurred and at six days. At six hours, plasma was obtained
for L-Arg levels and nitrite/nitrate (NOx) content. Renal tis-
sues were taken for histological evaluation of glomerular cell
It is now clear that fibrotic renal diseases are character-counts, macrophage infiltration (ED-1), and iNOS expression.
Glomeruli were isolated for detection of iNOS mRNA and ized by overexpression of the cytokine transforming
placed in culture to study the dependence of NO production growth factor-b (TGF-b) [1, 2]. Once TGF-b is overex-
on L-Arg concentration. In rats sacrificed at six days, L-Arg pressed, cells begin a fibrotic “repair” response involvingsupplementation was stopped 16 hours after ATS injection.
increased production and deposition of pathological ma-Fibrotic disease was evaluated by urinary protein excretion,
histological assessment of glomerular cell number, matrix accu- trix components and decreased turnover of matrix pro-
mulation, and production of transforming growth factor-b1 teins. Although the number of factors leading to TGF-b
and matrix components fibronectin and plasminogen activator overexpression is growing rapidly [3], all appear to in-
inhibitor type-1 (PAI-1) by isolated glomeruli in culture.
volve stimuli that cells may perceive as injurious. InResults. At six hours, the glomerular cell number was sig-
normal tissue injury, such as a skin wound, the “injury”nificantly reduced by ATS injection (P , 0.01) and further
significantly (P , 0.05) reduced by L-Arg feeding [normal and “repair” phases are followed by a resolution phase,
control (NC) 5 64.2 6 1, ATS 5 53.4 6 0.7, ATS 1 L-Arg 5 in which excess matrix is gradually removed. Although
50.8 6 0.7]. Disease increased macrophage infiltration and
perhaps simplistic, it is our current hypothesis that manyiNOS protein and iNOS mRNA levels markedly (P , 0.01),
fibrotic renal diseases result from repeated (or continual)whereas L-Arg feeding did not further increase these variables.
Plasma L-Arg levels (nmol/ml) were reduced by disease (NC 5 cycles of tissue “injury” and “repair” following so closely
121 6 9, ATS 5 84 6 13, P , 0.01) and elevated by L-Arg that resolution of pathological matrix does not occur.
feeding (ATS 1 L-Arg 5 166 6 12, P , 0.01). Plasma NOx The rate at which matrix accumulates depends on thewas significantly increased by ATS and further increased by
severity or frequency of repeated injury and can be grad-ATS 1 L-Arg (P , 0.05). Production of NOx by cultured
ual, as in diabetic nephropathy, or rapid, as in rapidlyglomeruli showed striking L-Arg concentration dependence in
progressive glomerulonephritis. In addition, at some
point the accumulated matrix impairs organ functionKey words: fibrotic disease, kidney, tissue injury, nitric oxide, TGF-b,
diabetic nephropathy, rapidly progressive glomerulonephritis. severely enough that injury becomes constant even if
the original stimulus to TGF-b overexpression is re-
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always present in the remaining nephrons, and the pro- cell lysis. We studied both the mechanism underlying
the L-Arg effect and the consequences on fibrosis at daycess becomes self-perpetuating.
The antithymocyte serum (ATS) model of glomerulo- 6 of disease.
nephritis involves a sequence of distinct “injury” and
“repair” phases of disease, making it amenable to dissec-
METHODS
tion of effects on both processes. An injection of an
Experimental designantibody to a thy-1.1–like antigen present in glomerular
mesangial cells initiates a complement-mediated lysis of Two experiments with three groups of eight rats each
were conducted. Groups were normal control, ATSa portion of these cells. This “injury” is followed by up-
regulation of TGF-b, and a fibrotic “repair” response alone, and ATS 1 L-Arg. L-Arg supplementation in-
volved 1% L-Arg added to drinking water from sevenfollows.
We have recently demonstrated that mesangial cell days before ATS injection to ensure total body equilibra-
tion until just after the injury phase of disease. The goallysis in this model is mediated through cytotoxic nitric
oxide (NO) production from substrate l-arginine was to isolate the effects of L-Arg supplementation on
the injury phase of disease. In experiment 1, the effect of(L-Arg) [4]. Both pretreatment with the NO synthase
(NOS) blocker l-monomethylarginine and restriction of L-Arg supplementation on the severity of ATS-induced
mesangial cell lysis and on variables known to be in-L-Arg intake during the period of lysis significantly re-
duced cell lysis and subsequent disease severity [4]. In volved in mesangial cell lysis was examined six hours
after disease induction. Previous studies had revealedaddition, a time course study of the activities of L-Arg
metabolic pathways revealed that mRNA for inducible that at this time, induction of iNOS had occurred, and
mesangial cell lysis was almost complete [5]. ExperimentNOS (iNOS) was seen only transiently during the mesan-
gial cell lysis phase of disease at six hours after ATS 2 was similar to experiment 1 except that L-Arg supple-
mentation was stopped at 16 hours after disease induc-injection [5]. Because iNOS utilization of L-Arg to pro-
duce NO has been reported to be very substrate depen- tion, and sacrifice occurred six days after ATS injection,
at a time when previous experiments had shown that thedent [6, 7], we hypothesized that L-Arg supplementation,
given during the period of mesangial cell lysis, might fibrotic response is maximal. The goal was to determine
whether changes in mesangial cell injury caused byprovide the transiently induced iNOS with additional
substrate, leading to greater NO generation and greater L-Arg supplementation given only until 16 hours after
disease induction were reflected in the severity of fibrosiscell lysis. We further hypothesized that this increase in
cell lysis would be reflected in the severity of the fibrotic at day 6.
response at day 6.
Methods used in both experimentsThere is now considerable evidence that manipulation
of L-Arg intake alters the course of disease in complex Materials. Unless otherwise indicated, materials,
chemicals, and culture media were obtained from Sigmaways. In addition to our published data showing that
restriction of L-Arg at the time of mesangial cell lysis Chemical Co. (St. Louis, MO, USA).
Animals. Male Sprague-Dawley (SD) rats (200 to 270 g)reduces lysis [4], other work has shown increased severity
of nephrotoxic nephritis if L-Arg is systemically removed were obtained from Sasco (Omaha, NE, USA) and fed
a normal protein diet (22% protein, Teklad diet No.by injection of arginase [8]. Further complexity comes
from studies showing that dietary L-Arg restriction dur- 86550; Teklad Premier Laboratory Diets, Madison, WI,
USA) with an L-Arg content of 0.85%.ing “repair” in ATS decreases the extent of fibrosis [9],
whereas supplementation improves functional and mor- Disease induction. Glomerulonephritis was induced
by tail vein injection of a submaximal dose of ATS underphological parameters in a number of other models of
experimental kidney disease [10–19]. Unlike ATS, in light methoxyflurane anesthesia. ATS was produced in
sheep as previously described [20]. ATS binds to amost of these models, the injurious stimulus is continual
and not immune mediated: glomerular hypertension in thy-1.1–like epitope on the surface of mesangial cells and
causes complement-dependent cell lysis. Control animals5/6 nephrectomy, hydronephrosis in ureteral obstruc-
tion, high glucose in diabetes, etc. Thus, there is no dis- were injected with equal volumes of phosphate-buffered
saline (PBS). Body weight, food, and water intake weretinct “injury” phase of disease, which can be studied
separately from the “repair” phase, as there is in ATS. monitored individually at the beginning and end of each
experiment.In an attempt to further unravel the complexities of
L-Arg manipulations so that decisions concerning use in Sacrifice. At sacrifice, animals were anesthetized with
ether. Following a midline abdominal incision, blood washumans may be grounded in a more complete under-
standing of mechanisms, we used the ATS model of drawn through a heparinized syringe from the lower
abdominal aorta. The blood was immediately centri-glomerulonephritis and studied L-Arg supplementation
given only before and during the period of mesangial fuged, and plasma was frozen at 2708C until analysis.
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The kidneys were subsequently perfused with 30 ml of DNA and hybridized with DNA probes labeled with 32P-
dCTP by random oligonucleotide priming (Boehringerice-cold PBS and harvested. For histological examina-
tion, cortical tissue was snap frozen and fixed in 10% Mannheim Biochemicals, Indianapolis, IN, USA). The
blots were washed in 2 3 SSC, 0.1% SDS at room tem-neutral-buffered formalin. Glomeruli from individual
rats were isolated by a graded sieving technique (150, perature for 15 minutes and in 0.1 3 SSC, 0.1% SDS at
558C for 30 minutes. DNA probes used were iNOS125, 106, and 75 mm mesh metal sieves) as described
previously [20]. (kindly provided by J. Pollock, Medical College of Geor-
gia) [21] and rat glyceraldehyde-3-phosphate dehydroge-Light microscopy. All microscopic examinations were
performed in a blinded fashion. Three micrometer sec- nase (GAPDH) cDNA [22].
Plasma L-arginine levels. These levels were deter-tions of paraffin-imbedded tissue were stained with peri-
odic acid-Schiff (PAS). Cells per glomerulus were mea- mined by a standardized high-performance liquid chro-
matography technique [23].sured by counting nuclei in 30 glomeruli of 80 to 100
mm diameter from each animal. Nitrite assay. Plasma NO2/NO3 levels were measured
by the Griess reaction [24] after nitrate reductase treat-Statistical analysis. Data are expressed as mean 6 sem.
Statistical analysis between the groups was performed ment. Briefly, samples were diluted 1:4 with PBS and
incubated at room temperature in the presence of 0.05by analysis of variance and subsequent t-testing with
Bonferroni correction for multiple comparison. A P mm NADPH and 0.05 U nitrate reductase (Boehringer
Mannheim Biochemicals). After 45 minutes of incuba-value of less than 0.05 was considered as significant.
tion at room temperature, proteins were precipitated
Methods used in experiment #1: Severity of mesangial with 70% zinc sulfate solution, and samples were centri-
cell injury fuged at 14,000 g for five minutes. One hundred microli-
ters of sample were then mixed with 100 ml Griess reagentImmunofluorescence microscopy. One to two mi-
crometer sections were made with a cryostat microtome [0.05% N-(1-naphthyl) ethylene diamine dihydrochlo-
ride, 0.5% sulfanilamide in 45% glacial acetic acid] in(Leica CM 1800; Leica Instruments, Nussloch, Ger-
many). Glomerular macrophage infiltration was ana- 96-well plates. After 10 minutes of incubation in the
dark, adsorbance was read at 546 nm in an automatedlyzed using a mouse monoclonal antirat monocyte and
macrophage IgG1 (ED-1; Serotec, Oxford, UK) as pri- plate reader (Thermomax; Molecular Devices, Menlo
Park, CA, USA). Standard samples were prepared withmary and a fluorescein isothiocyanate-coupled rat anti-
mouse antibody (Jackson ImmunoResearch Labora- sodium nitrate and were also nitrate reductase treated.
Glomerular nitric oxide production. The L-Arg con-tories, West Grove, PA, USA) as secondary antibody.
ED-1–positive cells in 20 glomeruli from each animal centration dependency of glomerular NO synthesis was
measured in glomeruli from four nephritic and threewere counted. Glomerular iNOS expression was ana-
lyzed using a rabbit antirat iNOS antibody (Alexis Cor- normal rats. Six hours after ATS or PBS injection, glo-
meruli were isolated from each individual animal andporation, San Diego, CA, USA) as primary and a rhoda-
mine-coupled antirabbit IgG (Jackson ImmunoResearch resuspended at a density of 2000 glomeruli/ml in phenol-
red-free RPMI 1640 with increasing L-Arg concentra-Laboratories) as secondary antibody. The intensity of
the glomerular staining was rated as follows: 0 5 no tions (0 to 1000 nmol/ml). Culture medium was prepared
using a RPMI 1640 Select-Aminet Kit (GIBCO BRL,staining; 1 5 weak and spotty staining; 2 5 moderate
and segmental staining; 3 5 moderately strong and seg- Grand Island, NY, USA). The medium was supple-
mented with 0.1 U/ml insulin, 100 U/ml penicillin, 100mental or moderate but diffuse staining; and 4 5 strong
and diffuse staining. Twenty glomeruli from each animal mg/ml streptomycin, and 25 mm HEPES buffer. After a
48-hour incubation at 378C/5% CO2, the samples werewere scored.
RNA preparation and Northern hybridization. Total centrifuged at 14,000 g for five minutes, and the cell-free
supernatant was stored at 2708C until nitrite analysisRNA was extracted by a guanidinium isothiocyante
method using Trizolw Reagent according to the manu- when 100 ml samples were mixed with 100 ml of Griess
reagent. Standards were prepared using sodium nitrite.facturer’s instructions. Glomeruli from four rats were
pooled for subsequent RNA extraction. For Northern
Methods used in experiment #2: Evaluation of theanalysis, RNA was denatured and fractionated by elec-
severity of fibrotic disease at day 6trophoresis through a 1.8% agarose gel (30 mg/lane) and
transferred to a Hybond nylon membrane (Amersham Matrix scoring. Glomerular matrix expansion was
evaluated by rating the mesangial matrix occupying eachCorp., Little Chalfont, Buckinghamshire, UK). Nucleic
acids were immobilized by ultraviolet irradiation. Mem- of 30 glomeruli per rat using the following rating system:
0 5 0%; 1 5 25%; 3 5 75%; and 4 5 100%.branes were prehybridized with 50% formamide, 10%
Denhardt’s solution, 0.1% sodium dodecyl sulfate Urinary protein excretion. Twenty-four hour urine
samples were taken eight and one days before, on the(SDS), 5 3 SSC, and 200 mg/ml denatured salmon sperm
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same day, and on the second and fifth days after ATS
or PBS injection. Proteinuria was measured using the
Bradford method and is expressed as mg per 24 hours.
Production of transforming growth factor-b1, fibro-
nectin, and plasminogen activator inhibitor type-1 by day
6 glomeruli in culture. Glomeruli were isolated from in-
dividual rats by graded sieving and resuspended in
DMEM supplemented with 0.1 U/ml insulin, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 25 mm HEPES
buffer. After 72 hours of incubation at 378C/5% CO2,
the samples were harvested and stored at 2708C until
analysis of glomerular TGF-b1, fibronectin, and plasmin-
ogen activator inhibitor type-1 (PAI-1) production.
TGF-b1 production of cultured glomeruli was measured
after acid activation using a commercially available kit
(Quantikinew; R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Fibronectin
and PAI-1 synthesis were measured with modified inhibi-
tory enzyme-linked immunosorbent assays (ELISA) ac-
cording to published methods [25]. Three samples from
each rat were analyzed and averaged, and then statistics
Fig. 1. Glomerular cell number as an indicator of mesangial cell lysiswere preformed. Each group thus contained data from six hours after injection of anti-thymocyte serum (ATS). Control ani-
eight rats. mals were injected with similar volumes of phosphate-buffered saline.
All groups were fed a normal protein diet (22% casein). Drinking water
in group “ATS 1 L-Arg” was supplemented with 1% L-Arg. *P , 0.01
vs. control; #P , 0.05 vs. ATS.RESULTS
L-Arginine intake
Supplementation of the drinking water with 1% L-Arg
tion does not alter macrophage infiltration in responseresulted in an approximate fourfold increase in daily
to ATS-induced disease.L-Arg intake (614 6 46 mg/day) compared with the
Inducible nitric oxide synthase expression. A ninefoldcontrol rats (158 6 13 mg/day) and those injected with
increase in glomerular iNOS staining intensity was seenATS and drinking tap water only (153 6 18 mg/day).
with ATS (Fig. 2B). Again, this increase was unchangedFood consumption and weight gain during the experi-
by L-Arg supplementation. The lack of an effect ofment were not different between the groups of animals
L-Arg supplementation on iNOS expression at the pro-(data not shown).
tein level was confirmed at the RNA level by Northern
Experiment #1 analysis of glomerular iNOS mRNA expression (Fig. 2
C, D). Although a 104-fold increase in diseased animalsMesangial cell injury. As shown in Figure 1, ATS in-
was seen, no further change was seen with L-Arg supple-jection resulted in a rapid drop in glomerular cell number
mentation. These results indicate that L-Arg supplemen-in six hours. Normal cell counts averaged 64.2 6 1.0 cells
tation does not affect iNOS expression at either theper glomerulus, whereas ATS animals’ cell counts were
mRNA or protein level, suggesting that any increase inreduced to 53.4 6 0.7 cells per glomerulus (P , 0.01).
iNOS activity and NO-mediated tissue injury is due toSupplementation of drinking water with 1% L-Arg re-
increased metabolism of L-Arg to NO because of in-sulted in a significant increase in mesangial cell lysis from
creased substrate availability.53.4 6 0.7 cells per glomerulus with ATS to 50.8 6 0.7
Plasma L-arginine and NOx content. An injection ofcells remaining after six hours (P , 0.05). This result
indicates that L-Arg supplementation leads to a small ATS and dietary L-Arg supplementation led to signifi-
cant changes in plasma L-Arg six hours after diseasebut significant increase in mesangial cell lysis compared
with rats given ATS alone. induction (Fig. 3A). An injection of ATS was associated
with an average decrease in plasma L-Arg from 121 6Glomerular macrophage infiltration. Macrophages mea-
sured six hours after ATS injection were increased nine- 9 nmol/ml to 84 6 13 nmol/ml, (P , 0.01), suggesting
increased utilization of L-Arg during the period of mes-fold with ATS (P , 0.01; Fig. 2A). A small but nonsig-
nificant increase in macrophages was seen with ATS 1 angial cell lysis. Supplementation with L-Arg more than
overcame this decrease, resulting in plasma L-Arg levelsL-Arg. These results suggest that L-Arg supplementa-
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Fig. 2. Glomerular monocyte/macrophage in-
filtration and inducible nitric oxide synthase
(iNOS) expression six hours after disease in-
duction. (A) Number of ED-1–positive cells
per glomerulus. (B) Glomerular staining for
iNOS. (C) Representative Northern blots of
iNOS and GAPDH mRNA. (D) Quantitation
of glomerular iNOS mRNA levels normalized
to GAPDH expression (N 5 4 blots). *P ,
0.01 vs. control.
Fig. 3. L-Arginine (L-Arg) concentrations
(A) and arterial nitrite/nitrate (NOx; B) levels
six hours after disease induction. All groups
were fed a normal protein diet. Drinking water
in group “ATS 1 L-Arg” was supplemented
with 1% L-Arg. *P , 0.01 vs. control; *P ,
0.01 vs. ATS, #P , 0.05 vs. ATS.
that were 137% of normal (166 6 12 vs. 121 6 9 nmol/ evidence for increased utilization of plasma L-Arg dur-
ing mesangial cell lysis came from measurement ofml) and 198% higher than in the ATS alone group (166 6
12 vs. 84 6 13 nmol/ml, P , 0.001; Fig. 3A). Further plasma NOx content, as shown in Figure 3B. Despite
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Fig. 4. In vitro nitrite/nitrate production by glomeruli harvested six
hours after disease induction in relation to the extracellular L-Arg
concentration. Symbols are: (j) ATS; (r) control.
their lower plasma L-Arg level, the plasma of ATS alone Fig. 5. Time course of proteinuria in rats injected with anti-thymocyte
serum (ATS) or phosphate-buffered saline (PBS; control). Symbolsrats contained significantly (P , 0.01) more nitrite and
are: (d) control; (r) ATS; (j) ATS 1 L-Arg. Drinking water in thenitrate, indicative of greater in vivo NO generation, than
group “ATS 1 L-Arg” was supplemented with 1% L-Arg for seven
normal animals. L-Arg supplementation resulted in a days before until 16 hours after ATS injection. *P , 0.05 vs. ATS.
further significant increase in NOx compared with ATS
alone, consistent with additional L-Arg utilization by
iNOS in glomeruli during mesangial cell lysis (ATS 5
after ATS injection in vivo should be very much higher31.0 6 1.3 nmol/ml; ATS 1 L-Arg 5 35.7 6 1.1 nmol/
in ATS 1 L-Arg compared with ATS alone animals.ml, P , 0.05).
Dependence of glomerular nitric oxide production on
Experiment #2l-arginine concentration. Because the previously men-
Proteinuria. Rats given L-Arg supplemented drinkingtioned data suggested that L-Arg–supplemented rats had
water before and during ATS-induced mesangial cellhigher L-Arg utilization but similar glomerular iNOS
lysis developed significantly higher proteinuria at day 2expression compared with ATS-injected animals with a
of disease (P , 0.05; Fig. 5). This difference in protein-normal L-Arg intake, we determined the NOx produc-
uria was not seen at day 5, suggesting that it results fromtion of nephritic glomeruli isolated six hours after disease
differences in injury that are not carried through to laterinduction in the presence of increasing L-Arg concentra-
phases of disease.tions. As shown in Figure 4, the NOx synthesis of ne-
Fibrotic disease at day 6. From past experience withphritic glomeruli was highly dependent on the extracellu-
the ATS model, we know that extracellular matrix accu-lar L-Arg concentration. A dramatic increase in NOx
mulation at day 6 is greatly increased, although the peaksynthesis was seen starting at 50 nmol/ml, which peaked
is several days later in Sprague-Dawley rats. However,at 500 nmol/ml L-Arg. In contrast, NOx production by
other measures of disease, including production ofglomeruli from control rats did not change with different
TGF-b1, fibronectin, and PAI-1, which are very reliableL-Arg concentrations in the culture medium. Taken with
variables of disease severity, peak at day 6. As seen inthe data on plasma L-Arg levels shown in Figure 3A,
Figure 6A, a large increase in the quantity of pathologicalthese data indicate that at six hours after ATS injection,
matrix is seen with ATS alone at day 6 (P , 0.01) com-plasma L-Arg levels are in the range in which small
pared with control. L-Arg supplementation before andincreases in L-Arg concentration lead to large differ-
during the period of mesangial cell lysis results in a smallences in NO generation. Thus, glomerular iNOS utiliza-
tion of substrate L-Arg and NO generation six hours but significant (P , 0.05) increase in matrix accumula-
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Fig. 6. Effect of L-Arg supplementation on
the anti-thymocyte serum (ATS)-induced tis-
sue injury as measured by the disease severity
six days after injection with ATS or phos-
phate-buffered saline (PBS; control). Drink-
ing water in the group “ATS 1 L-Arg” was
supplemented with 1% L-Arg for seven days
before until 16 hours after ATS injection.
Shown are the following: glomerular matrix
accumulation (A) and glomerular production
of TGF-b1 (B), fibronectin (C), and PAI-1
(D) in culture supernatant after 72 hours.
*P , 0.01 vs. control, #P , 0.05 vs. ATS.
tion. Similar patterns were seen for glomerular produc- in this study, when dietary intake or endogenous utiliza-
tion of TGF-b1, fibronectin, and PAI-1 (Fig. 6 B, C, and tion is increased as during inflammation, plasma L-Arg
D). Thus, the small increase in mesangial cell lysis seen levels change.
at six hours with L-Arg supplementation (Fig. 1) results With L-Arg as its substrate, iNOS generation of large
in small but significant increases in fibrotic disease at amounts of NO has been identified as a key mediator
day 6. of the mesangial cell injury that follows the injection of
Glomerular cell number. The day 6 glomerular cell ATS [4]. A similar critical role of NO in renal tissue
numbers for the three groups of rats were 64.6 6 3.0 injury has been shown in models of acute ischemic renal
cells per glomerulus for normal control, which increased failure and lupus nephritis [28, 29] and is suggested in
to 75.4 6 1.8 for the ATS alone group (P , 0.01). A experimental kidney transplant rejection [30]. This study
further significant (P , 0.05) increase to 82.5 6 2.8 for demonstrates that in ATS-induced glomerulonephritis,
the ATS 1 L-Arg group was seen. Taken with the data dietary L-Arg supplementation given during the time of
presented in Figure 1, this indicates that compared with cell lysis results in a significant augmentation of mesan-
ATS alone, L-Arg feeding during the period of mesangial gial cell damage (Fig. 1). L-Arg administration did not
cell lysis results in fewer cells per glomerulus at six hours appear to reduce the inflammatory response following
but a greater number of cells per glomerulus at day 6. ATS injection because macrophage infiltration and glo-
merular iNOS and protein levels did not differ in L-Arg–
supplemented and –nonsupplemented rats (Fig. 2). TheDISCUSSION
ED-1 staining here contrasts with a report that L-Argl-Arginine has been classified as a semi-essential
supplementation reduces renal macrophage infiltrationamino acid [26]. Under normal physiological conditions,
in obstructive nephropathy and puromycin-induced ne-endogenous L-Arg synthesis is sufficient to maintain
phrosis [12].whole body L-Arg metabolic homeostasis. Endogenous
Two measures suggest that at six hours after diseaseL-Arg synthesis occurs primarily in the proximal tubule
induction, utilization of L-Arg to produce NO is in-of the kidney using the nonprotein amino acid l-citrul-
creased by ATS and further increased when ATS is givenline as precursor [27]. The rate of L-Arg production in
renal tubules is constant, however, and, as demonstrated to L-Arg–supplemented rats. First, plasma L-Arg levels
Peters et al: L-Arg supplementation and renal fibrosis 2271
are lower and plasma NOx content is higher in ATS results from the reaction of the cytotoxic radical peroxi-
nitrite and the amino acid tyrosine in proteins. Peroxini-alone rats (Fig. 3), and second, plasma NOx levels are
significantly higher in ATS rats with L-Arg supplementa- trite is an important mediator of NO cytotoxicity and
is a product of the reaction of NO with superanions.tion than in ATS rats drinking tap water only (Fig. 3).
Further confirmation of these findings were in vitro data Immunohistochemical studies have shown evidence for
increased staining of nitrotyrosine in a number of humanin which nephritic glomeruli showed markedly higher
NOx production at L-Arg concentrations comparable to diseases, including atherosclerosis, myocardial ischemia,
inflammatory bowel disease, and septic lung disease [43].those seen in the plasma of animals with L-Arg supple-
mentation. These results strongly support the concept In human kidney disease, Kashem et al have detected
increased expression of iNOS mRNA and protein in thethat the detrimental effect of L-Arg supplementation on
ATS-induced glomerulonephritis is directly mediated by majority of patients with mesangioproliferative glomeru-
lonephritis, primarily IgA nephropathy [44]. The iNOSgreater substrate availability. When L-Arg is stopped
16 hours after ATS injection and the “repair” phase enzyme was colocalized with areas of macrophage infil-
tration, but was also found in resident renal cells. Inter-proceeds with normal L-Arg intake, the increased injury
that occurred by six hours continues to be reflected by estingly, the iNOS expression correlated with the sever-
ity of histological signs of renal damage, as well as thesmall but significant increases in glomerular cell number,
matrix accumulation, and production of TGF-b1, fibro- loss of renal function [44]. We have also reported a
preliminary study showing significantly increased iNOSnectin, and PAI-1 at six days of disease (Fig. 6). Other
disease models in which L-Arg administration worsens protein expression in glomeruli and the tubulointerstit-
ium of patients with acute and chronic renal transplanttissue injury appear to share the feature that NO syn-
thesis is greatly increased through induction of NO rejection (abstract; Ikegaya et al, J Am Soc Nephrol
7:1563, 1996). Finally, nitrotyrosines have recently beensynthase. These include immune-mediated dermal vas-
culitis, hypoxic lung injury, toxic colitis, and brain reper- detected in failing human kidney transplants [45]. There-
fore, it appears likely that induction of iNOS plays a rolefusion [31–34].
In terms of the relevance of rat models of tissue injury, in a number of human disorders.
In addition to being a substrate for iNOS, L-Arg is athere has been some debate about whether humans re-
spond with similar induction of iNOS. In rodents, the substrate for several other NO synthases, including a
constitutive enzyme produced by endothelial cells [35].central role of iNOS expression in host defense, tumor
killing, and autoimmune tissue destruction in vivo is un- Renal endothelial cells produce small quantities of NO
by this enzyme. This endothelial NO serves as a criticaldisputed [35]. However, a high output iNOS pathway has
been difficult to show in humans. Rodent macrophages in vasodilator and may play a protective role in both normal
glomeruli and those exposed to increased pressure. It isvitro produce large amounts of NO in response to stimuli
such as lipopolysaccharides or cytokines such as inter- generally believed that the mechanism underlying the
therapeutic effects seen with dietary L-Arg supplemen-feron-g or tumor necrosis factor-a, whereas human mac-
rophages or monocytes in vitro show little or no response tation in a number of models of renal disease is increased
endothelial NO generation [46].[36]. On the other hand, there is considerable recent in
vivo evidence that this pathway is operating in humans. l-Arginine is also a substrate for the generation of
agmatine, polyamines, and l-proline [27]. Both cell pro-The expression of iNOS and increased NO synthesis
has been shown in cells from several human diseases, liferation, dependent on polyamine generation, and col-
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a NO pathway [42]. Similar to rodents, the killing of the the start of the “repair” phase of disease, resulted in less
fibrosis at day 7 [9].pathogen Leishmania major by human macrophages is
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